Does hypothyroidism cause elevated homocysteine levels?

Hypothyroidism significantly impacts sulfur amino acid metabolism, leading to elevated plasma homocysteine levels—a condition known as hyperhomocysteinemia. This metabolic shift is observed across the spectrum of thyroid dysfunction and is particularly relevant for its contribution to cardiovascular risk.

Clinical and effectiveness evidence

• Meta-analyses and large-scale observational studies consistently demonstrate that patients with overt hypothyroidism have significantly higher homocysteine concentrations compared to euthyroid individuals.
• The magnitude of this elevation can be substantial; studies have reported mean homocysteine levels of approximately 24.45 µmol/L in hypothyroid patients, more than double the 11.48 µmol/L typically seen in healthy controls.
• Clinical trials confirm that this relationship is likely causal, as levothyroxine (L-T4) replacement therapy effectively reduces homocysteine levels back toward the normal range as thyroid stimulating hormone (TSH) and free thyroxine (FT4) levels normalize.
• This association carries clinical weight because elevated homocysteine in these patients frequently correlates with markers of vascular damage, such as increased carotid intima-media thickness and dyslipidemia.

Mechanistic explanations

Thyroid hormones act as critical regulators of the enzymatic machinery required for homocysteine clearance via two primary pathways:

• Remethylation pathway: Hypothyroidism is associated with the downregulation of methylenetetrahydrofolate reductase (MTHFR). This reduction in MTHFR expression limits the availability of 5-methyltetrahydrofolate, the essential methyl donor needed to recycle homocysteine back into methionine.
• Transsulfuration pathway: Low thyroid states reduce the activity of cystathionine-β-synthase (CBS) and cystathionine-γ-lyase (CGL). These enzymes are responsible for the irreversible conversion of homocysteine into cystathionine and subsequently into cysteine and glutathione.
• Metabolic outcomes: The impairment of these pathways not only results in the accumulation of homocysteine but also diminishes the production of downstream antioxidants like glutathione, further exacerbating oxidative stress.

Bottom line

Hypothyroidism causes hyperhomocysteinemia by impairing the expression and activity of MTHFR, CBS, and CGL. This elevation is a reversible metabolic consequence of thyroid hormone deficiency that contributes to the broader cardiovascular risk profile of hypothyroid patients.